THE CASE
A 17-year-old male presented to his doctor in June 2000 with pain in his lower-left chest. The patient had no significant medical history and was in good health and participating in athletic activities when the pain began, shortly before his presentation. A chest X-ray revealed a non displaced fracture of the ninth left anterior rib and absence of the tenth, eleventh, and twelfth ribs, which was thought to be a con genital anomaly. The pain continued, prompting multiple medical visits. Five months later, the patient noticed a small, slowly enlarging mass in the lower-left chest wall accompanied by moderate, but worsening back pain. After a further 4 months, a repeat chest X-ray showed a large, left pleural effusion and erosion of lateral spine pedicles from the T10 to the T12 vertebrae. MRI demonstrated involvement of the lower cervical spine as well as the lower thoracic spine. In March 2001, a CT scan demonstrated the absence of the ninth to twelfth left ribs, erosion of the pedicles of the lower thoracic vertebrae, tumor invasion into the spine and pleural effusion (Figure 1 A-C) .
The patient underwent an incisional biopsy in March 2001, which revealed lymphangiomatosis. Several weeks later, a spine stabilization procedure was performed to prevent vertebral body collapse of the T10 to T12 vertebrae. Resection of bone and soft tissue from the T9 to T10 vertebrae demonstrated angiomatous proliferation, consistent with Gorham's lymphangiomatosis.
The patient was started on a 2-year course of thalidomide (200 mg/day) and celecoxib (200 mg twice daily). In February 2002, an MRI scan showed the presence of persistent disease in the spine (Figure 1 D,E) . Progressive pain prompted evaluation by the Pediatric Hematology/ Oncology service at the authors' institution in July 2002 and the patient commenced interferon (IFN)-α2b (3 million units/day) at this time.
Background A 17-year-old male presented with pain in his lower-left chest. He had no significant medical history and was previously in good health. He had a fractured ninth left anterior rib and the tenth, eleventh and twelfth ribs were absent, which was thought to be a congenital anomaly. Several months later, he presented again with back pain, an enlarging mass in the lower-left chest wall, erosion of the lateral pedicles of the lower thoracic vertebrae and pleural effusion.
In January 2003, pamidronate (90 mg/month) was started in an attempt to inhibit the debilitating osteolysis. In February 2003, the doses of thalidomide, IFN-α2b, and celecoxib were doubled. In March 2003, the patient showed signs of muscle wasting and complained of fatigue and generalized aches. As no evidence of substantial benefit from IFN-α2b therapy had been observed, this drug was discontinued, and pamidronate was switched to intravenous zoledronate (4 mg/month). Radiotherapy was considered at this point, but the volume of normal lung tissue in required radiation fields, and the patient's already compromised respiratory status, precluded the safe delivery of a radiation dose sufficient to achieve local-disease control (40-45 Gy 1 ).
Despite pharmacological intervention, the patient's clinical status continued to deteriorate, with dyspnea and worsening pain. The patient subsequently developed a right-sided chylothorax and his dyspnea became disabling. In early August 2004 he underwent a thoracotomy, pleurectomy, and talc pleurodesis to re-expand the right lung, but could not be extubated after surgery. During surgery, a massively thickened parietal pleura ( Figure 2A ) and abundant, leaky lymphatic vessels on the inner chest wall ( Figure 2B ) were observed. In September 2004, the patient was transferred from the intensive care unit following prolonged admission due to profound muscle weakness, ascites and pseudomonal colonization of his lungs.
To determine the presence of blood and lymphatic vessel markers on the endothelial cells of the abnormally proliferating vasculature in this patient's Gorham's lymphangiomatosis, specimens taken during surgery were stained for the panendothelial marker CD31 (platelet endothelial cell adhesion molecule), lymphatic vessel endothelial hyaluronan receptor-1 (LYVE-1) and VEGF receptor (VEGFR)-3. All vessel structures expressed CD31 ( Figure 3A ) and approximately 90% of the CD31-positive endothelial cells also expressed LYVE-1, indicating that the proliferating vasculature associated with Gorham's lymphangiomatosis consisted mainly of lymphatic endothelium ( Figure 3B ). Staining detected VEGFR-3, the receptor for VEGF-C and VEGF-D, in immune cells/macrophages in the tissue and in less than half of the proliferating vessels ( Figure 3C ). The lymphatic endothelium was also examined for expression of lymphangiogenic or angiogenic growth factors that might drive the vessel proliferation in Gorham's lymphangiomatosis, and thus form a potential therapeutic target for blockade with therapeutic inhibitors. The patient's Gorham's lymphangiomatosis tissue, archived non-Gorham's lymphangiomatosis (control) and several normal archived tissues, were stained immunohistochemically for VEGF, VEGF-C, platelet-derived endo thelial growth factor receptor (PDGFR)-β and epidermal growth factor (EGF). VEGF, VEGF-C and EGF did not stain strongly in Gorham's lymph angiomatosis or in control lymphangiomatosis compared with normal human skin. PDGFR-β staining was present in endothelial cells and cells directly adjacent to most vessels in the patient's lymphangiomatosis ( Figure 3D , E), but not in control lymph angiomatosis ( Figure 3F ), normal skin or normal pleura.
To confirm the potential role of the PDGFR-β receptor pathway in Gorham's lymphangiomatosis, enzyme-linked immunosorbent assays (ELISAs) for PDGF-BB and VEGF were performed on the patient's plasma. The circulating level of PDGF-BB was elevated 7-fold (108 ± 4 pg/ml) compared with control samples (15 ± 4 pg/ml), while VEGF level was within normal limits (100 ± 14 pg/ml). A multiplexed ELISA found that plasma basic fibroblast growth factor was also slightly elevated (27 ± 1 pg/ml; normal range 0-14 pg/ml), while placental growth factor (24 ± 1 pg/ml; normal range 0-24 pg/ml) and soluble VEGFR-1 (157 ± 11 pg/ml, normal range 55-123 pg/ml) were within normal limits. Circulating endothelial cells, which are thought to be mobilized by angiogenic factors such as VEGF, were relatively abundant, representing 2.3% of all mononuclear cells (compared to an average of 1.7% measured in ten rectal cancer patients 2 and almost undetectable levels in healthy individuals 3 ). Collectively, these data suggested the diagnosis of Gorham's lymph angiomatosis with expression of PDGFR-β and elevated circulating PDGF-BB.
As a result of the elevated circulating levels of PDGF-BB and the presence of PDGFR-β in the tumor, the patient was started on imatinib mesylate (400 mg/day) in early October 2004. After 6 days of this treatment, however, his respiratory status declined with reaccumulation of pleural fluid. Imatinib mesylate was discontinued, and the patient's respiratory status improved over the following week. The patient was discharged from hospital in late October 2004. A second trial of imatinib mesylate (200 mg/day) was commenced 4 weeks later when the patient's overall function had improved, but this was aborted when he reported increasing respiratory difficulty within 3 days of starting medication. During subsequent months, the patient's respiratory status and overall condition gradually deterior ated as a result of disease progression and he died 46 months after the initial diagnosis. Recently, a number of growth factors that stimulate the proliferation of lymphatic vessels and lymphangiogenesis have been identified, 7, 8 including VEGF-A, VEGF-C, and PDGF-BB. The PDGF-signaling pathway stimulates tumor-cell proliferation, angiogenesis, and pericyte recruitment to tumor blood vessels. 9 Interestingly, a recent report showed that PDGF-BB expression is associated with the formation of abnormal initial lymphatics in human lymphedema distichiasis, 10 whereas another report suggested that PDGF-BB is directly lymphangiogenic. 11 The immunohistochemical profiles of several of these lymphangiogenic factors were examined in tissue specimens from this patient. More than 90% of the proliferating vessels expressed LYVE-1, a relatively specific marker for lymphatic endothelial cells that is also expressed in liver and spleen sinusoids. 12 This finding suggests that these vessels were mainly of lymphatic endo thelial origin, consistent with what has previously been proposed. 13 These vessels also expressed PDGFR-β and this finding, together with the elevated level of circulating PDGF-BB in the patient's plasma, support a potential role for the PDGF-signaling pathway in Gorham's lymphangiomatosis. Interestingly, strong staining of PDGFR-β, VEGF, VEGF-C, or EGF was not detected in two other patients with lymph angiomatosis who were used as control tissues for this case. Unfortunately, it was not possible to determine whether PDGFR-β was phosphorylated in this patient, as reliable immuno histochemical staining for phospho-PDGFR-β could not be obtained. It is possible that the patho genesis of these disorders is different; lymphatic mal formations that arise during early childhood might stem from aberrant sequestrations of lymphatic vessels, 13 while the acquired proliferation of small lymphatics observed in Gorham's disease might be driven by lymph angiogenic growth factors, such as PDGF-BB.
The number of molecules known to be involved in lymphangiogenesis is increasing, providing new targets for the treatment of tumors consisting of proliferating lymphatic vessels. Angiopoietin-1, angiopoietin-2, VEGF-D and hepatocyte growth factor are other molecules known to play a role in lymphatic vessel growth and maturation. These molecules were not assessed in this case, as there are no drugs currently available that interrupt their molecular signaling pathways.
TREATMENT AND MANAGEMENT
Current successful therapies for Gorham's disease are limited to aggressive surgery aimed at preventing reaccumulation of fluid in the pleural cavity, IFN-α2b, which is also used to treat other highly vascular lesions including hemangiomas and giant-cell lesions, 14, 15 and radiotherapy. 1 This patient also received bisphosphonates in the hope that their antiresorptive and anti angiogenic properties might arrest the unremit ting progression of his osteolytic disease. 6, 16 The evidence for expression of PDGF-BB and its receptor PDGFR-β in Gorham's disease suggests that targeted therapy with PDGFR-blocking agents, such as imatinib mesylate, might also be beneficial in certain cases of lymphangio matosis. Imatinib mesylate 17 and other agents that block the PDGFR pathway are, however, associated with fluid exudates and edema, which can cause pleural effusions, pulmonary edema, ascites, or pericardial effusion. The mechanism by which imatinib mesylate causes these imbalances in tissue-fluid homeostasis is currently unknown. A preclinical animal study is needed to determine the mechanism, the understanding of which would help guide the use of imatinib mesylate in the future. PDGFR blockade also has other possible toxic effects involving the integuementary, hematologic, dermatologic, and gastrointestinal systems. This patient had a pre-existing pleural effusion and compromised pulmonary function, making fluid retention and its deleterious effects on respiratory function the most alarming potential adverse event. Although worsening pleural effusions and deteriorating respiratory function necessitated discontinuation of imatinib mesylate in this patient, this novel therapy could be of benefit to patients with PDGF-driven lymphangiomas in extrapleural sites. Alternatively, if complications related to fluid exudates develop, agents directed at blocking this toxic side effect might be employed. These include molecules that reduce micro vascular permeability, such as VEGF inhibiting anti bodies and phosphotyrosine kinase inhibitors. 18, 19 
CONCLUSION
Gorham's disease is a rare and devastating form of lymphangiomatosis with unknown etiology. The data from this patient show that the PDGFR signaling pathway could be implicated in the pathogenesis of this disease. Unfortunately, in this case, declining respiratory function after the start of imatinib mesylate therapy necessitated cessation of the drug before the potential efficacy of PDGFR-β blockade could be determined. Clinicians should be aware of the possibility that PDGFR signaling could be important in Gorham's disease. Future evaluation of PDGFR-β and its ligands in patients with Gorham's disease could provide new insight into the pathogenesis of this disease.
As a larger portfolio of specific inhibitors becomes available to clinicians, the ability to identify therapeutics that will positively impact individual patients will become increasingly important. Similarly, the toxicity profiles of therapeutic agents should be considered when tailoring treatments. This case illustrates the potential for individualized, targeted therapy and highlights the need to tailor therapy based on both the presence of therapeutic targets and the complications those therapies might induce in the individual patient.
